The vasculitides are complex immune mediated diseases, the pathogenesis of which remains unknown. A symposium organized by the Section of Rheumatology & Rehabilitation presented an update on recent progress.
Dr David Scott (Consultant Rheumatologist at Norfolk
and Norwich Hospital) began his lecture 'Management and classification of vasculitis: the present', by defining vasculitis as iriflammatory cell irifiltration and necrosis 1 blood vessels. He reminded us that Zeek was the first to classify vasculitis in 1952 and it was not until 1990 that the American College of Rheumatology published its recommended classification criteria for seven of the major vasculitides", More recently the Chapel Hill Consensus Conference redefined many of the major vasculitides and also reclassified them according to the size of blood vessels involved/. However, the classification used by Dr Scott and his colleagues separates conditions which commonly affect medium sized arteries and small vessels from those which predominantly involve only small vessels (Table 1) 3. The former group of conditions are further distinguished by their frequent association with antineutrophil cytoplasmic antibodies (ANCA), their response to immunosuppressive treatment and a pathogenetic mechanism which is probably unrelated to the formation of immune complexes.
Dr Scott then showed us epidemiological data from the Norfolk Health Region collected between 1988~94 based on these criteria't- 5. These showed that the commonest vasculitis was systemic rheumatoid vasculitis (SRV, 12.5/ Table 1 Classification of vasculitis million), followed by Wegener's granulomatosis (WG, 8.5/ million), microscopic polyangiitis (MPA) and Churg-Strauss (CS) vasculitis (2.S/million each). Interestingly, the incidence of SRV is twice that in the 1981 Bath survey. Whether SRV is becoming more common is unclear. Unlike RA, in which there is a female predominance, SRV is commoner in males with a life-time risk of 1:9 compared to 1:38 in females. The prevalences of WG and CS vasculitis were higher in the Norfolk survey (WG: 8.S/million, CS: 6/million) than in previous studies (WG: 0.S-2.8/million, CS: l/million). Interestingly, classical PAN conforming to the criteria of the Chapel Hill Conference was not found in the Norwich survey.
Prognosis in vasculitis varies, but in general old age and gastrointestinal, cardiac and renal involvement augur a poor outcome. In PAN and WG the 2-year survival rates without treatment were 10%. Steroid treatment alpne improved survival in PAN to 50% but did not affect WG. Combining steroid with cyclophosphamide (CP) improved the 2-year survival rate to 80% and 90% in PAN and WG respectively. The National Institutes of Health recommended treatment regimen for WG includes 2 mg/kg/day of oral CP together with prednisolone (1 mg/kg/day, alternate days) for 1 month. This leads to significant improvement in 90% and remission in 75% of the patients, although in 50% of the patients the disease will relapse", Intermittent intravenous cyclophosphamide (Lv. CP) has been compared with oral CP in a small study which showed no significant difference in the rate of remission and degree of clinical improvement. Intravenous CP given fortnightly may be associated with a slightly lower rate of infections, whereas i.v, CP given monthly has a slightly higher relapse rate. On the other hand oral CP was associated with a higher incidence of cystitis. Other side effects of CP included neoplasm (7.6%), infection (11%), and bone marrow suppression (21% more effective in preventing relapse than plasmapheresis and steroid alone'', The treatment regimen used by Dr Scott is an intravenous pulse of CP 15 mg/kg and methylprednisolone 1 g repeated at 2-weekly intervals on two occasions, followed by oral pulses of CP 5 mg/kg and prednisolone 100 mg for 3 consecutive days every 2 weeks. The dose of CP should be adjusted according to the white cell count and if there is renal impairment the dosage should be reduced. The interval of treatment could be gradually increased after four to six courses. For different types of vasculitis, specific treatments are available. Intravenous gammaglobulin has been a major advance in the treatment of Kawasaki diseases. Cyclosporin A is useful for autoimmune eye disease and Behcet's disease. Methotrexate is used in scleritisl'' and nail fold infarcts but, in general, is ineffective for severe vasculitis. Plasma exchange is useful for cryoglobulinaemia, paraproteinaemia and possibly pulmonary haemorrhage. It is rarely used on its own but often in combination with steroid and CP. Other agents which have been tried include prostacyclin for SRV ulcers, co-trimoxazole for WG, thalidomide for Behcet's disease and pentoxifylline as a cytokine inhibitor; however, their therapeutic efficacy remain unproven.
Assessment of disease outcome and treatment efficacy in vasculitis remains problematic, particularly in diseases such as WG in which relapse is common. Dr Scott stressed that assessment should include measurements of vasculitis disease activity (e.g. Birmingham Vasculitis Activity Score)!", organ damage and functional outcome (e.g. Short Form 36).
Dr Martin Lockwood (Senior Lecturer and Honorary
Consultant Physician, Cambridge University) discussed the pathogenesis of vasculitis and hypothesized that systemic vasculitis is an autoimmune disease in which autoantibodies such as anti-neutrophil cytoplasmic antibodies (ANCA) are pivotal in the pathogenesis12. He reminded us that there are two main types of ANCA classified according to the immunofluorescent staining pattern: cytoplasmic ANCA (cANCA) and perinuclear ANCA (pANCA). cANCAs are found mainly in WG patients and are directed against the antigen proteinase 3. pANCA, which often targets myeloperoxidase, is found in a variety of conditions including RA and infection. Other ANCAs target a variety of antigens as shown in Table 2 13 . Recently a new ANCA antigen, bactericidal/permeability increasing factor (BPI), has been found!". BPI is a 55 kDa azurophilic protein expressed on the surface membrane of neutrophils. It has a role in neutralizing endotoxin and therefore protects against Gram negative bacterial infections. Dr Lockwood showed data implicating anti-BPI antibody in the pathogenesis of vasculitis in patients with certain infections. In a group of 14 patients with uncomplicated idiopathic bronchiectasis seven were anti-BPI antibody positive while in patients with pseudomonas colonized cystic fibrosis 60/66 patients had IgG anti-BPI and 55/66 had IgA anti-BPI antibodies. Morevover, 6/66 patients with high anti-BPI titre had vasculitis. Both forced expiratory volume and forced vital capacity were subnormal in anti-BPI antibody positive patients.
Dr Lockwood hypothesized that ANCA antigens such as BPI could be expressed on the surface of neutrophils. Emerging evidence suggests that ANCA binding to these surface antigens can activate neutrophils15 as well as increasing their binding to endothelial cells'". Autoantigens such as BPI could also stimulate T cells and result in inllammation-". Hence immunotherapy targeting T cells may be effective in the treatment of vasculitis. Indeed, humanized anti -T cell monoclonal antibodies have been used in the treatment of vasculitis. Mathieson et aJ. reported that a combination of two humanized monoclonal antibodies, Campath-IH and anti-CD4, induced prolonged disease remission in a patient with systemic vasculitis refractory to steroid and cyclophosphamide17. Campath-IH targets the pan-T-cell surface marker CDw52. It has a human IgGI Fc that fixes complements efficiently, resulting in cell lysis. Campath-l H was administered intravenously for 5-10 days. Treatment resulted in a marked reduction in the number of circulating lymphocytes, in particular CD4 cells. In this patient a non-lytic anti-CD4 monoclonal antibody was also used after Campath-l H treatment. Disease improved after Campath-IH treatment but tended to relapse. However, additional therapy with anti-CD4 monoclonal antibody resulted in prolonged remission.
Since then Campath-l H has been used in a number of vasculitides including Sjogren's syndrome with promising results 18 • In particular, 13 ANCA-positive WG patients were treated with Campath-I H. Twelve patients had complete disease remission and only three had relapsed. Three patients in this study died from other causes which did not seem related to treatment or WG. Clearly, controlled trials will be necessary to establish its place in the treatment of systemic vasculitis.
Dr Graham Hughes (St Thomas' Hospital and the
Rayne Institute) in his talk on 'The antiphospholipid syndrome' (APS) summarized the progress made in 10 years of clinical, laboratory and animal model research in this condition. The routinely-used ELISA for antiphospholipid (aPL) antibodies has been well standardized by regular international workshops. One of the early clinical findings was that these patients develop arterial thromboses, contrasting with most of the genetically determined clotting disorders which predispose to venous thrombosis. It seems to be the brain that is picked out and there is a feeling that neurological clinical features are the commonest. Possible reasons for this include the relative absence of thrombomodulin from the vascular endothelium of the brain and this is an area of current research. The range of presentation includes small and large strokes, subtle cognitive impairment and multi-infarct dementia. Cross-sectional studies of patients with stroke have shown the proportion of patients with aPL antibodies varying from 6.8% in Barcelona to 18% of a group of young Italian patients. Livido reticularis is a useful pointer to this aPLassociated thrombotic tendency. Transverse myelopathy, a rare feature of lupus, shows a strong association with aPL. Anti-phospholipid antibodies are found in some patients with choreo-athetosis and other movement disorders and there is anecdotal information that the abnormal movements may stop with anticoagulation. Seizure disorders are also seen in many patients with aPL. Heart valve abnormalities in patients with lupus are associated with aPL. Sometimes this is rapidly progressive and associated with splinter haemorrhages and clubbing, a picture resembling that of infective endocarditis. The incidence of myocardial infarction appears not to be increased in these patients. Kidney disease has not been a prominent feature of the APS but recent careful studies have shown the presence of micro-and macro-thromboses in these patients' kidneys and one should think of renal involvement if, for instance, a patient with APS suddenly develops hypertension. Addison's disease may be associated with APS in some patients, due to infarction of the adrenal glands. Liver involvement is seen, including the wellrecognized association with Budd-Chiari syndrome.
Two HLA studies have shown an association of primary APS with DR7, but the numbers are still small. Weare awaiting information from several studies on whether the oral contraceptive pill and smoking enhance the disease. Although primary APS is an autoimmune disease and the patients may have some features of systemic lupus erythematosus (SLE), they very seldom progress to typical SLE. In one study this sequence was observed in only one of 39 primary APS patients followed for 9 years. Immunological studies of aPL have shown a group of antibodies directed against the phospholipid component of membrane which bind to anionic phospholipids and the binding is absolutely dependent on a plasma protein cofactor Ihglycoprotein 1 (pz-GP 1). The presence of this cofactor is necessary for the binding of anti-cardiolipin antibodies from patients with autoimmune disease but not fro~patients with infection. The possible role of pz-GPI in the pathogenesis of APS is under investigation.
Dr Hughes went on to consider the management of APS. 'No treatment' is probably the best management for asymptomatic patients. Aspirin is the mainstay of treatment of patients with mild symptoms and provides peace of mind for the doctor although long-term follow-up may show that it is not that good. Immunosuppression does not help. Anti-malarial drugs have an anti-thrombotic effect and their use in patients with SLE features and APS is being investigated.
The management of pregnancy in women with APS is a good source of data because of the relatively short-term monitoring required. Before 1985 the fetal wastage suffered by women with aPL in Dr Hughes' lupus pregnancy clinic was 72%. In the subsequent 5 years this wastage was halved to 38%, mainly attributable to regular Doppler monitoring and early delivery of women whose fetuses showed poor growth. Early fetal wastage has been little reduced. Dr Hughes and his colleagues are investigating the use of low molecular weight heparin in pregnancy because it has the advantages of not crossing the placenta, having a long halflife and being amenable to monitoring. In a group of 27 women with APS who had all previously had a thrombosis in pregnancy they used Fragmin O.2-D.6 units/mL until 6 weeks postpartum. There were no thrombotic event in these pregnancies and 15 successful pregnancies. However, one woman, a previously fit gymnastics teacher, developed osteoporosis with two vertebral crush fractures. In view of the risk of osteoporosis with long-term heparin, an alternative regimen might be heparin in the first trimester only and warfarin in the remainder of the pregnancy.
In adult medicine the commonest problem encountered is the patient who has had recurrent thromboses, possibly including a cerebral thrombosis. A recent retrospective
